CU20110244A7 - Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios - Google Patents

Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios

Info

Publication number
CU20110244A7
CU20110244A7 CU2011000244A CU20110244A CU20110244A7 CU 20110244 A7 CU20110244 A7 CU 20110244A7 CU 2011000244 A CU2011000244 A CU 2011000244A CU 20110244 A CU20110244 A CU 20110244A CU 20110244 A7 CU20110244 A7 CU 20110244A7
Authority
CU
Cuba
Prior art keywords
molecular entities
general formula
esteroid
neuroactive
spi
Prior art date
Application number
CU2011000244A
Other languages
English (en)
Inventor
Pupo Laura García
Figueredo Yanier Núñez
Morales Juan Enrique Tacoronte
Reyes Yamila Verdecia
Rodríguez Estael Ochoa
Castro Armando Zaldo
Original Assignee
Ct De Investigación Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Investigación Y Desarrollo De Medicamentos Cidem filed Critical Ct De Investigación Y Desarrollo De Medicamentos Cidem
Priority to CU2011000244A priority Critical patent/CU20110244A7/es
Priority to US14/368,668 priority patent/US20150140088A1/en
Priority to EP12821233.9A priority patent/EP2801581A1/en
Priority to CA2861958A priority patent/CA2861958A1/en
Priority to ARP120105012A priority patent/AR089491A1/es
Priority to BR112014016127A priority patent/BR112014016127A2/pt
Priority to JP2014549357A priority patent/JP2015506929A/ja
Priority to IN1419MUN2014 priority patent/IN2014MN01419A/en
Priority to PCT/CU2012/000008 priority patent/WO2013097835A1/es
Publication of CU20110244A7 publication Critical patent/CU20110244A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/005—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con la química, la farmacéutica y en particular con la obtención de nuevas entidades moleculares, derivados esteroidales, con acción sobre el Sistema Nervioso Central. A partir de la diosgenina, la cual constituye una sapogenina de origen natural, se obtienen derivados esteroidales espirostánicos hexacíclicos de fórmula general I-IV, mediante reacciones con compuestos de tipo oxidantes, epoxidantes, etc., así como posteriores transformaciones a algunos de ellos. Las entidades moleculares de fórmula general I-IV contienen el núcleo ciclopentanoperhidrofenantreno, donde el ciclo A son anillos espirostánicos sustituidos con diferentes átomos electronegativos. Estas entidades moleculares presentan acción anti-glutamatérgica y anti-inflamatoria, utilizables en el tratamiento de las enfermedades inflamatorias crónicas y agudas, neurodegenerativas, neuropsiquiátricas y neurológicas.
CU2011000244A 2011-12-27 2011-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios CU20110244A7 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CU2011000244A CU20110244A7 (es) 2011-12-27 2011-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
US14/368,668 US20150140088A1 (en) 2011-12-27 2012-12-27 Spirosteroid systems acting as neuroprotective and anti-inflammatory agents
EP12821233.9A EP2801581A1 (en) 2011-12-27 2012-12-27 Spirosteroidal systems having neuroactive, anti-inflammatory effects
CA2861958A CA2861958A1 (en) 2011-12-27 2012-12-27 Spirosteroidal systems having neuroactive, anti-inflammatory effects
ARP120105012A AR089491A1 (es) 2011-12-27 2012-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
BR112014016127A BR112014016127A2 (pt) 2011-12-27 2012-12-27 sistemas espiroesteroidais com efeitos neuroativos e anti-inflamatórios, e, composição farmacêutica
JP2014549357A JP2015506929A (ja) 2011-12-27 2012-12-27 神経保護剤及び抗炎症剤として作用するスピロステロイド系
IN1419MUN2014 IN2014MN01419A (es) 2011-12-27 2012-12-27
PCT/CU2012/000008 WO2013097835A1 (es) 2011-12-27 2012-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti- inflamatorios

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2011000244A CU20110244A7 (es) 2011-12-27 2011-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios

Publications (1)

Publication Number Publication Date
CU20110244A7 true CU20110244A7 (es) 2013-08-29

Family

ID=47665756

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000244A CU20110244A7 (es) 2011-12-27 2011-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios

Country Status (9)

Country Link
US (1) US20150140088A1 (es)
EP (1) EP2801581A1 (es)
JP (1) JP2015506929A (es)
AR (1) AR089491A1 (es)
BR (1) BR112014016127A2 (es)
CA (1) CA2861958A1 (es)
CU (1) CU20110244A7 (es)
IN (1) IN2014MN01419A (es)
WO (1) WO2013097835A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104558085B (zh) * 2014-12-16 2016-08-17 吉林农业大学 萘甲酸环戊烷并多氢菲酯b及其提取方法和药物用途
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
CN110452283B (zh) * 2019-04-24 2020-09-25 西南民族大学 一种抗肿瘤季铵盐类衍生物及其制备方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1058988B (de) * 1957-05-03 1959-06-11 British Drug Houses Ltd Verfahren zur Herstellung von 3ª‰-Hydroxy-6-methyl-?-steroiden
US3002969A (en) * 1957-05-03 1961-10-03 British Drug Houses Ltd 3beta-hydroxy-6-methyl-delta5-steroids and method of preparation
US3105068A (en) * 1961-03-09 1963-09-24 Sato Yoshio Improved preparation of allopregnenolone and pregnadienolone from tomatidine and solasodine
ES359406A1 (es) * 1967-10-23 1970-06-01 Erba Carlo Spa Procedimiento para la preparacion de nuevos derivados de (25r)-3 beta-amino-5alfa, 22alfa-espirostano.
US5116829A (en) 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
JPH04230696A (ja) * 1990-12-28 1992-08-19 Sanwa Shiyouyaku Kk 新規なステロイド系化合物および制癌剤
US5629295A (en) * 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
CA2136803A1 (en) 1993-12-22 1995-06-23 Kazumi Ogata Steroid derivatives
CU22860A1 (es) * 1995-10-12 2003-05-26 Univ La Habana Espirostanonas con funciones oxigenadas en el anillo a. como reguladores del crecimiento vegetal y su procedimiento de obtención
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
IT1311922B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
CN100430062C (zh) 2002-03-15 2008-11-05 萨马里坦药品公司 神经保护性螺甾烯醇药用组合物
JP4573157B2 (ja) * 2002-03-27 2010-11-04 フィトファーム・パブリック・リミテッド・カンパニー 治療方法ならびにサポゲニンおよびその誘導体の使用
KR20100093621A (ko) * 2002-03-27 2010-08-25 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
JP2011027429A (ja) * 2009-07-21 2011-02-10 Kirin Holdings Co Ltd 液体クロマトグラフィーを用いたグリコアルカロイド類の精製および分析法
AU2011281336B2 (en) * 2010-07-20 2015-03-05 Junaxo, Inc. Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders

Also Published As

Publication number Publication date
EP2801581A1 (en) 2014-11-12
JP2015506929A (ja) 2015-03-05
BR112014016127A2 (pt) 2017-07-04
WO2013097835A1 (es) 2013-07-04
IN2014MN01419A (es) 2015-04-03
US20150140088A1 (en) 2015-05-21
AR089491A1 (es) 2014-08-27
CA2861958A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
NI201200066A (es) Métodos de síntesis y purificación de compuestos heteroarilos
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CU20130137A7 (es) Derivados de ácido 3- fenilpropiónico ramificados y su uso
SV2011004058A (es) Anticuerpos humanizados especificos de la forma protofibrilar del peptido beta-amiloide
BR112015023001A8 (pt) composições resultantes da retirada de exons para o tratamento de distrofia muscular.
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CO6781507A2 (es) Novedosos derivados heterociclicos
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
UY35700A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
EP2895593A4 (en) PREPARATION OF ORGANIC ACIDS BY FERMENTATION AT LOW PH
UY32426A (es) Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
EA201290091A1 (ru) Изоксазолидиновые производные
EA201391173A1 (ru) Изоксазолидиновые производные
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
BR112016001928A2 (pt) derivados de piperidina ureia
CU20110244A7 (es) Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
MX2020011330A (es) Proceso para la preparacion de la forma 1 del propionato de fluticasona.
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico